Neoadjuvant Immunotherapy Followed by Surgery Compared with Upfront Surgery Alone in Operable Colon Cancer with Deficient Mismatch Repair: Modeling Oncological Outcomes and Numbers Needed to Treat
In unselected patients with colon cancer having dMMR, recurrence risk is very low after surgery. Assuming a curative effect of neoadjuvant immunotherapy beyond surgery alone, the NNT would be at least 20 patients to prevent one cancer death over surgery alone.
Authors
- Kjetil Søreide (ORCID: https://orcid.org/0000-0001-7594-4354)
- Tran Kenneth
- Ananda Marina
- Claudia Zaharia (ORCID: https://orcid.org/0000-0002-4893-1029)
- William McChesney Martin (ORCID: https://orcid.org/0000-0001-7703-1508)
- Kanani Arezo
- Veen Torhild
- Lea Dordi
Institutions
- Stavanger University Hospital (NO)
- University of Bergen (NO)
Publication Details
- Journal
- Annals of Surgical Oncology
- Published
- 2024-12-30
- DOI
- https://doi.org/10.1245/s10434-024-16755-y
- Citations
- 4
- Primary Topic
- Colorectal and Anal Carcinomas
- Type
- article
- Field-Weighted Citation Impact
- 2.29
Funders
- Helse Vest